Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Aug 1;210(3):365-367.
doi: 10.1164/rccm.202404-0787LE.

Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy

Linus Piehler  1 , Ralf Thalemann  1 , Christine Lehmann  1 , Mirjam Stahl  1   2   3 , Marcus A Mall  1   2   3 , Simon Y Graeber  1   2   3
Affiliations
Comment

Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy

Linus Piehler et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Changes in symptoms of depression after initiation of elexacaftor/tezacaftor/ivacaftor (ETI) and in the pre-ETI era. Alluvial graphics of paired assessment of the Patient Health Questionnaire-9 (PHQ-9) (A) from a prospective observational trial at baseline and 3 months after initiation of ETI (n = 70) (2) and (B) from the yearly mental health screening at the Cystic Fibrosis Center at Charité – University Medicine Berlin in the years 2017 to 2020 derived from the German Cystic Fibrosis Registry (Mukoviszidose e.V.) (n = 68). Categories represent no or minimal (scores = 0–3; blue), mild (scores = 4–6; green), moderate (scores = 7–9; yellow) and severe (scores = 10–21; red) symptoms of depression as assessed by the PHQ-9. (A) is adapted from our previous study (2) to highlight the course of PHQ-9 scores of the 67.6% patients who reported no or minimal symptoms of depression after the initiation of ETI.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Lee TWR, Duff AJA. Questions and answers? Depression symptoms associated with elexacaftor/tezacaftor/ivacaftor treatment for cystic fibrosis. Am J Respir Crit Care Med . 2024;209:239–241. - PMC - PubMed
    1. Piehler L, Thalemann R, Lehmann C, Thee S, Röhmel J, Syunyaeva Z, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis. Front Pharmacol . 2023;14:1179208. - PMC - PubMed
    1. Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, et al. Elexacaftor/tezacaftor/ivacaftor treatment and depression-related events. Am J Respir Crit Care Med . 2024;209:299–306. - PMC - PubMed
    1. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. VX17-445-102 Study Group Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med . 2019;381:1809–1819. - PMC - PubMed
    1. Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles. Am J Respir Crit Care Med . 2022;205:540–549. - PubMed

MeSH terms